CoChat

Highly Potent and Specific GSK‐3β Inhibitors That Block Tau Phosphorylation and Decrease α‐Synuclein Protein Expression in a Cellular Model of Parkinson's Disease

Kozikowski, Alan P., Gaisina, Irina N., Petukhov, Pavel A., Sridhar, Jayalakshmi, King, LaShaunda T., Blond, Sylvie Y., Duka, Tetyana, Rusnak, Milan, Sidhu, Anita · 2006 · ChemMedChem
Cited by 103

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Research by Klein and co‐workers suggests that the inhibition of GSK‐3β by small molecules may offer an important strategy in the treatment of a number of central nervous system (CNS) disorders including Alzheimer's disease, Parkinson's disease, and bipolar disorders. Based on results from kinase‐screening assays that identified a staurosporine analogue as a modest inhibitor of GSK‐3β, a series of 3‐indolyl‐4‐indazolylmaleimides was prepared for study in both enzymatic and cell‐based assays. Most strikingly, whereas we identified ligands having poor to high potency for GSK‐3β inhibition, only ligands with a Ki value of less than 8 n M, namely maleimides 18 and 22, were found to inhibit Tau phosphorylation at a GSK‐3β‐specific site (Ser 396/404). Accordingly, maleimides 18 and 22 may protect neuronal cells against cell death by decreasing the level of α‐Syn protein expression. We conclude that the GSK‐3β inhibitors described herein offer promise in defending cells against MPP+‐induced neurotoxicity and that such compounds will be valuable to explore in animal models of Parkinson's disease as well as in other Tau‐related neurodegenerative disease states.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cmdc.200500039

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 103

Metadata

Authors
Kozikowski, A. P., Gaisina, I. N., Petukhov, P. A., Sridhar, J., King, L. T., Blond, S. Y., Duka, T., Rusnak, M., & Sidhu, A.
Venue
ChemMedChem
Publisher
Wiley
Published
2006-02-03
Volume
1
Issue
2
Pages
256-266
ISSN
  • 1860-7179 (ISSN-L)
  • 1860-7187
OpenAlex
W2137617843
Cited by
103
References
4
FWCI
4.12
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Highly Potent and Specific GSK‐3β Inhibitors That Block Tau Phosphorylation and Decrease α‐Synuclein Protein Expression in a Cellular Model of Parkinson's Disease. https://app.cochat.ai/papers/10.1002/cmdc.200500039
The paper
Kozikowski, A. P., Gaisina, I. N., Petukhov, P. A., Sridhar, J., King, L. T., Blond, S. Y., Duka, T., Rusnak, M., & Sidhu, A. (2006). Highly Potent and Specific GSK‐3β Inhibitors That Block Tau Phosphorylation and Decrease α‐Synuclein Protein Expression in a Cellular Model of Parkinson's Disease. ChemMedChem. https://doi.org/10.1002/cmdc.200500039

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.